Le Lézard
Classified in: Business
Subject: STR

IIROC Trade Resumption - CPTR


TORONTO, Nov. 29, 2017 /CNW/ - Trading resumes in:

Company: Captor Capital Corp.

CSE Symbol: CPTR

Resumption (ET): 11:30 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions


These press releases may also interest you

at 09:17
Canadian Investment Regulatory Organization Trading Halt - MDCX
The following issues have been halted by CIRO Company: Medicus Pharma Ltd. TSX-Venture Symbol: MDCX  All Issues: Yes Reason: Pending News Halt Time (ET): 9:09 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a...

at 09:17
Risk3sixty Named a Pacesetter for the Sixth Consecutive Year
Risk3sixty, a leading cybersecurity technology and consulting firm, announced today that it has been named a Pacesetter Award winner by the Atlanta Business Chronicle for a sixth consecutive year. The Pacesetter Awards celebrate the 100...

at 09:15
Mullen Announces New CARB Approval for 2025 Class 3 EV Cab Chassis Truck
via IBN...

at 09:15
SEATTLE KRAKEN INCREASES BROADCAST AND STREAMING ACCESS THROUGH PARTNERSHIPS WITH TEGNA AND PRIME VIDEO
The Seattle Kraken today announced new multi-year agreements with TEGNA and Prime Video to offer more options for fans to watch their games throughout the Pacific Northwest....

at 09:15
Thirty Madison's Nurx and Cove partner with Talkspace to expand mental health support for more than half a million women
Thirty Madison, the specialty telemedicine company operating Keeps, Cove, and Nurx, today announced a partnership with Talkspace, a  leading online behavioral health company, to expand comprehensive mental health offerings for more than half a...

at 09:15
RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Neovascular AMD Treatment
RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies, announced today it has successfully closed its first seed funding round, raising $16.5 million to propel its mission to develop and...

More news about Business...


News published on and distributed by: